Are there any termination fees related to Evofem’s (EVFM) agreement with Windtree?

No, Evofem states there are no termination or other fees payable in connection with ending the agreement with Windtree. This means the company does not incur a specified financial penalty solely from the mutual termination of the License and Supply Agreement.

Evofem ends Windtree PHEXXI supply agreement with no fees

Evofem Biosciences, Inc. reports that it has mutually terminated its License and Supply Agreement with Windtree Therapeutics, Inc., which had made Windtree a manufacturer and supplier of PHEXXI® (lactic acid, citric acid, and potassium bitartrate).

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Evofem Biosciences, Inc. reports that it has mutually terminated its License and Supply Agreement with Windtree Therapeutics, Inc., which had made Windtree a manufacturer and supplier of PHEXXI® (lactic acid, citric acid, and potassium bitartrate). The parties entered into a Termination Agreement effective March 13, 2026.

The company states that there are no termination or other fees payable in connection with ending this agreement, helping avoid an immediate financial charge from this change. Certain customary provisions of the original agreement that are meant to survive termination will remain in effect.

8-K Event Classification

2 items: 1.02, 9.01

2 items

Item 1.02 Termination of a Material Definitive Agreement Business

A significant contract was terminated, which may affect business operations or revenue.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What agreement did Evofem Biosciences (EVFM) terminate with Windtree Therapeutics?

Evofem Biosciences terminated its License and Supply Agreement with Windtree Therapeutics. This agreement had designated Windtree as a manufacturer and supplier of PHEXXI, Evofem’s lactic acid, citric acid, and potassium bitartrate product, before both parties agreed to end the arrangement.

When did the Evofem (EVFM) and Windtree Termination Agreement become effective?

The Termination Agreement between Evofem and Windtree became effective on March 13, 2026. On that date, both companies mutually agreed to end the prior License and Supply Agreement covering manufacturing and supply of PHEXXI while allowing certain surviving provisions to remain in force.

What product was covered by the Evofem (EVFM) and Windtree License and Supply Agreement?

The agreement covered PHEXXI, described as lactic acid, citric acid, and potassium bitartrate. Under the terminated License and Supply Agreement, Windtree had agreed to become a manufacturer and supplier of PHEXXI for Evofem before both parties decided to end the arrangement.

Do any terms of the Evofem–Windtree agreement continue after termination?

Yes, Evofem notes that certain customary provisions of the original agreement that, by their terms, survive termination remain in effect. These surviving clauses typically address matters like confidentiality or other post-termination obligations defined in the original contract.

Where can investors find the full Evofem (EVFM) Termination Agreement with Windtree?

The full Termination Agreement between Evofem and Windtree is filed as Exhibit 10.1. It is included with the company’s current report and is incorporated by reference, providing the complete legal terms beyond the brief summary disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/19/2026 - 04:05 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 13, 2026

EVOFEM BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-36754	20-8527075
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

7770 Regents Road, Suite 113-618

San Diego, California 92122

(Address of principal executive offices)

(858) 550-1900

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.02. Termination of Material Definitive Agreement.

As previously disclosed in Current Reports on Form 8-K dated March 26, 2025 and April 3, 2025, on March 20, 2025, Evofem Biosciences, Inc. (the “Company”) entered into a License and Supply Agreement with Windtree Therapeutics, Inc. (“Windtree”), which was amended on March 28, 2025 (as amended, the “Agreement”), pursuant to which Windtree agreed to become a manufacturer and supplier of PHEXXI® (lactic acid, citric acid, and potassium bitartrate).

On March 13, 2026, the Company and Windtree entered into a Termination Agreement (the “Termination Agreement”) pursuant to which the parties mutually consented to the termination of the Agreement, effective as of such date. There is no termination or any other fees payable in connection with the termination of the Agreement. Certain customary provisions of the Agreement that by their terms survive termination remain in effect.

The foregoing summary of the Termination Agreement does not purport to be complete and is qualified in its entirety by reference to the Termination Agreement, a copy of which is filed as Exhibit 10.1, to this Current Report on Form 8-K, and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
10.1		Termination Agreement by and between the Company and Windtree Therapeutics, Inc. dated March 13, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	EVOFEM BIOSCIENCES, INC.

Dated: March 19, 2026	By:	/s/ Saundra Pelletier
		Saundra Pelletier
		Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

EX-10.1 EX-10.1 26.3 KB